A new study presented at The Endocrine Society's annual meeting found that obese insulin-resistant women lost more weight on a lower-carbohydrate diet compared to a traditional low-fat diet. After three months, the lower-carb group lost an average of 19.6 pounds, while the low-fat group lost 16.2 pounds.
A team of researchers has developed a more consistent method for isolating pancreatic islet cells from brain-dead donors using ductal injection, resulting in three type 1-diabetes patients becoming insulin-independent. The study's success rate surpasses the standard 50% with an impressive 80% clinical islet transplantation rate.
Scientists from the Helmholtz Centre in Braunschweig, Germany, have created a new and cheaper way to produce insulin. The new method uses yeast Pichia pastoris to increase the yield of an insulin precursor, reducing costs. This breakthrough could make insulin more affordable for people in developing countries.
A new nanotech breath sensor can detect Type I diabetes by measuring acetone levels in exhaled breath. The device is sensitive enough to detect high concentrations of acetone, even in moist air, allowing for early diagnosis and monitoring of diabetic ketoacidosis.
Research at the University of Texas Medical Branch found that elderly people's muscles don't respond to insulin by expanding their blood vessels like younger people do. This response is necessary for muscle protein synthesis and growth, with implications for improving strength and health in older adults.
A study using Goto-Kakizaki rats found that Roux-en-Y gastric bypass surgery increases post-surgical expression of PDX-1 and promotes regeneration of β-cells, leading to improved diabetes management. This research provides a new basis for surgical treatment of type 2 diabetes.
A study found that individuals with a family history of type 2 diabetes gain significantly more weight after consuming excess calories compared to those without such a history. Insulin resistance, a precursor to the disease, was also observed in the genetically prone group.
Researchers discovered insulin's properties reduce inflammation in fat tissue, a key factor in developing insulin resistance and type 2 diabetes. Identifying the inflammatory molecule IL-6 and protein PKCdelta improved understanding of signalling mechanisms that can lead to medicines to reduce inflammation and related disorders.
A Mayo-led research team has developed potent molecules that can inhibit the breakdown of insulin in the body, keeping it working longer and potentially leading to new treatments for diabetes. The discovery may also have implications for other diseases involving insulin, such as Alzheimer's disease.
A new report in Cell Metabolism shows that insulin-resistant blood vessels develop plaques twice as large as normal ones and are more prone to atherosclerosis. Insulin signaling helps prevent fatty plaque buildup, suggesting treatments targeting blood vessels may be beneficial for people with diabetes.
Researchers have identified small molecules that bind to TrkB, a protein involved in nerve cell survival, and demonstrated their potential in treating neurodegenerative conditions. Additionally, a new compound has been found to prevent anaphylactic shock by targeting the SphK1-S1P pathway, which may lead to the development of new thera...
A new artificial pancreas system has been developed to mimic the body's natural glucose control mechanism, using insulin and glucagon hormones. The system was tested in a clinical trial with 11 adults with type 1 diabetes, showing that it can maintain near-normal glucose levels without causing hypoglycemia.
Researchers have invented a 'smart' insulin protein molecule that binds less to cancer receptors and self-assembles under the skin. This new form of insulin reduces the risk of cancer associated with obesity and excess insulin in Type-2 diabetes patients.
Scientists found that alpha cells can spontaneously reprogram into beta cells, restoring insulin production and potentially treating type 1 diabetes. The study demonstrated that removing nearly all beta cells allowed the pancreas to regenerate new ones, offering a new strategy for regenerating insulin-producing cells.
A new ultra-rapid acting mealtime insulin is orally inhaled for absorption via the lung, mimicking the natural early insulin response. This innovative technology uses a delivery system that applies to other drugs currently injected, with potential benefits including reduced hypoglycemia and weight gain.
Researchers at UT Southwestern Medical Center found that leptin administration showed better management of blood-sugar variability and lipogenesis, the conversion of simple sugars into fatty acids. Leptin therapy also reduced food intake and increased lean body mass in non-obese type 1 diabetic mice.
Scientists have determined the structure of a previously unseen part of the insulin receptor, which could lead to new treatments for diabetes. Understanding how insulin interacts with the receptor is crucial for developing effective therapies.
Researchers explore the link between diabetes treatment and eating disorders, finding that insulin therapy can cause weight gain, increase hunger, and dysregulate appetite hormones. This can lead to unhealthy behaviors such as skipping or reducing insulin doses, which can exacerbate diabetes complications.
A review of over three decades of studies suggests that insulin therapy may increase cancer risk, particularly in those with type 2 diabetes. The study's findings also highlight the potential benefits of metformin treatment in reducing cancer incidence.
Researchers at the University of Cambridge found that first-generation artificial pancreas systems can lower risk of low blood sugar emergencies while sleeping and improve diabetes control. The study showed improved target blood glucose levels, minimized low blood sugars, and reduced hypoglycemia.
Scientists at the University of Cambridge have developed a new algorithm that significantly improves glucose control and reduces the risk of hypoglycemia in children with type 1 diabetes. The study shows that using an artificial pancreas system overnight can halve the time blood glucose levels fall below 3.9mmol/l, while sleeping.
A closed-loop 'artificial pancreas' system can improve blood sugar control in young patients with type 1 diabetes, reducing the risk of nocturnal hypoglycaemia and achieving good glucose levels. The study found that children with the artificial pancreas maintained normal blood glucose levels for 60% of the time.
Researchers at the Salk Institute for Biological Studies have made a breakthrough in understanding how stress hormones affect insulin-producing cells. The study found that the hormone CRF can increase the rate of cell growth and proliferation, which could potentially lead to new approaches for treating type 1 diabetes.
SourceJDRF·JournalProceedings of the National Academy of Sciences·DateFeb 3, 2010
Research finds that intensive glucose control can lower blood glucose too far, increasing mortality risk in patients with type 2 diabetes. The study suggests that blood glucose level targets should have both upper and lower limits to minimize the risk of hypoglycemia.
Treating adults with septic shock with intensive insulin therapy did not result in a reduced risk of in-hospital death compared to conventional insulin therapy. Patients treated with intensive insulin experienced significantly more episodes of severe hypoglycemia than those in the conventional treatment group.
Scientists have identified common features of super active insulins, shedding light on their molecular structure and interaction with insulin receptors. The research holds promise for developing more sophisticated treatments for Type I diabetes, potentially offering controlled or injection-free therapies.
A team of researchers identified ten new genetic markers associated with biological traits underlying type 2 diabetes and three new variants linked to raised glucose levels. The study helps unravel the complex biology of type 2 diabetes and paves the way for further research on treatments.
Dr. Donald F. Steiner has made significant contributions to the understanding of insulin secretion and related disorders through his research on proinsulin and C-peptide measurement. His work has led to major improvements in therapeutic insulin development, diagnosis of pancreatic tumors, and islet transplants.
Dr. Donald F. Steiner has made significant contributions to understanding insulin secretion and glucose metabolism, including the discovery of proinsulin and clinical applications of C-peptide radioimmunoassay. He will receive a Certificate of Honor and US$150,000 in recognition of his outstanding research achievements.
A team of researchers found that high levels of urea produce toxic molecules in fat cells, leading to insulin resistance and characteristics of end-stage kidney disease. Blocking the effects of high urea levels may improve quality of life and lifespan for individuals with chronic kidney failure.
Researchers from UC San Diego used a systems biology approach to determine how core biochemical pathways are altered in skeletal muscle cells and fat cells in people with insulin resistance. The study found that common drugs for treating insulin resistance, such as TZDs, alter these pathways, leading to improved drug therapies.
Scientists have discovered a direct link between insulin and core body temperature, finding that insulin injection in specific brain areas increases metabolism, brown adipose tissue activity, and core temperature. The study suggests a potential therapeutic area for future drug design and new insights into obesity and diabetes.
A specific gene in the pancreas affects insulin secretion, leading to improved blood glucose regulation and potential new treatments for diabetes. The discovery opens a new understanding of diabetes pathophysiology.
Researchers design nanowire-based beads that release drugs in the gut, improving absorption and reducing degradation. The technology may also be used for delivering drugs to mucosal tissues like the nose, lungs, or vagina.
Research found that mice lacking a crucial protein for insulin production have lower circulating insulin levels and impaired granule function. The discovery may explain a portion of Type 2 diabetes and help identify rare genetic cases.
A team from CHEO Research Institute used genetic engineering to remove the Lkb1 gene from beta cells of laboratory mice, resulting in increased insulin production and storage. The improved function lasted at least five months, even on a high-fat diet.
Monash researchers found that antioxidants can prevent beneficial effects of ROS on insulin action in early stages of Type 2 diabetes. Elevated ROS levels in genetically-modified mice prevented insulin resistance and diabetes induced by a high-fat diet.
Researchers at University of Texas Medical Branch at Galveston have found that increasing insulin levels can restore impaired muscle-building processes in elderly individuals. This breakthrough suggests a novel approach to addressing age-related muscle loss and has implications for developing new treatments.
A recent study found inhaled insulin to be inferior to traditional insulin injections in maintaining optimal blood glucose levels. Despite this setback, researchers continue to explore alternative routes of insulin delivery, including MannKind Corporation's Technosphere Insulin.
Dr. Francesca M. Spagnoli is investigating the possibility of repurposing hepatic cells to produce insulin in diabetic patients. Her research aims to identify molecular signals that determine why one progenitor cell develops into a hepatic cell and another into a beta cell.
A new study has found that genes regulating insulin also alter the timing of the circadian clock, suggesting novel therapies for metabolic disease. Hundreds of genes were identified as affecting the clock's timing, with seven genes involved in insulin control also influencing its rhythms.
Treatments like insulin and metformin do not reduce inflammatory biomarkers, such as hsCRP, despite improving glucose control. No consistent association was found between glucose reduction and improvement in inflammatory status.
A breakthrough discovery identifies a new gene called Insulin Receptor Substrate 1 (IRS1) that affects how the body responds to insulin, leading to insulin resistance. The study found a single-nucleotide polymorphism in the IRS1 gene that reduces its activity by 40%, making it harder for insulin to work effectively.
Scientists have discovered a genetic variation that impairs the body's muscle cells ability to use insulin effectively, leading to insulin resistance and type 2 diabetes. The study highlights a potential new target for scientists developing treatments for this disease.
Scientists at Eastern Virginia Medical School have identified a vital step in the development of Type 1 diabetes and hope to develop a novel therapeutic approach by blocking an enzyme called 12-LO. Preliminary results are promising, and further research is underway.
A 12-week moderate aerobic exercise program improved insulin sensitivity in both lean and obese sedentary adolescents, increasing fitness without the need for weight loss. The study suggests an aerobic program like this could be a useful tool in preventing obesity-related illnesses.
Researchers developed a molecular sensor to measure zinc concentration and location in cells for the first time. The sensor revealed high zinc ions inside pancreatic cells where insulin is packaged, suggesting its involvement in type 2 diabetes.
Pittsburgh researchers have found a molecular link between insulin resistance and inflammation, suggesting a novel target for diabetes treatment. The study reveals that protein Fox01 stimulates inflammatory white blood cells, leading to increased production of cytokine IL-1B, which interferes with insulin signaling.
A new study has found that high serum insulin levels are associated with an increased risk of prostate cancer, even within the normal range. Insulin-like growth factors may play a role in prostate cancer development.
A recent study at UT Southwestern Medical Center suggests that taking insulin as the initial treatment for type 2 diabetes can be just as effective as other options, reducing low-blood-sugar events and weight gain. Insulin-based therapy has been shown to improve patient satisfaction and overall quality of life.
Researchers at Tel Aviv University developed a tablet-based treatment for Type 1 diabetes, FTS, which restores insulin production and reduces disease progression. The compound has shown positive results in inhibiting diabetes and has the potential to fast-track through FDA regulatory hurdles.
A study published in the Archives of Internal Medicine found that intensive glucose control halves the rate of eye and kidney damage in people with longstanding type 1 diabetes. The study also showed lower rates of cardiovascular disease events and improved vision loss rates compared to conventional control.
Researchers at Northwestern University use nanodiamonds to deliver insulin for wound healing, demonstrating a method for localized release of therapeutic proteins. The nanodiamond-insulin clusters show promise for wound-healing applications and could be integrated into various treatments.
Men who walk or bike to work are less likely to be overweight or obese and have healthier triglyceride levels, blood pressure, and insulin levels. Active commuting is also associated with improved fitness and reduced environmental impact.
Researchers at Albert Einstein College of Medicine found a strong association between elevated insulin levels and increased breast cancer risk in postmenopausal women. Women with higher insulin levels were more than twice as likely to develop breast cancer compared to those with lower insulin levels, especially among lean women.
A Monash University study has discovered a critical link between obesity and Type 2 diabetes, revealing that fat cells release PEDF, which triggers insulin resistance. Blocking PEDF reverses these effects, suggesting a potential breakthrough in treating the disease.
The International Diabetes Federation (IDF) is investigating possible links between insulin glargine and increased cancer risk based on 2009 Diabetologia study findings. The organization emphasizes that people needing insulin should not stop taking the drug, urging them to consult their doctors for advice.
A study published in Diabetologia suggests that insulin analogue glargine may increase the risk of cancer in diabetes patients. The analysis found a statistically significant association between glargine use and an increased risk of malignancies, with a dose-dependent relationship observed.
A modest reduction in dietary carbohydrates increased feelings of fullness and stabilized blood sugar levels after meals. The study found that even without weight loss, a moderate-carb diet improved ratings of fullness before and after eating.
A new study finds that optimal medical therapy is equally effective as revascularization procedures like bypass surgery or angioplasty in lowering the risk of death and cardiovascular events in patients with diabetes and stable coronary heart disease. Insulin-providing and insulin-sensitizing drugs are also shown to be equally effective.